Skip to main content

Languages

Knowledge translation: the number, coverage, and application of Cochrane reviews in China

Date and Location

Session: 

P3.111

Date

Sunday 22 September 2013 - 10:30 - 12:00

Location

Presenting author and contact person

Presenting author

Mingming Zhang

Contact person

Mingming Zhang
Abstract text
Background: It was reported that Chinese authors were the third largest contributor in the Cochrane Collaboration. However, little is known about the coverage and application of Cochrane Reviews in China. Objectives: To investigate the number, coverage and application of Cochrane Systematic Reviews (CSRs) in China. Methods: We searched Archie from 2006 to 2011 for the information of reviews published by at least one Chinese author and the distribution of Chinese authors in CRG. We searched the Chinese Science Citation Database (CSCD) using the term “Cochrane” from 1989 to Dec. 2012 to know the application of CSRs. Microsoft Excel 2007 was used to perform data extraction and analysis. Results: The number of publication for full Reviews by at least one Chinese author was increasing from the year 2009 to 2011, with 143, 177 and 217 respectively. The distributions of Chinese authors in top ten groups were: Hepato-Biliary (192), Renal (173), Stroke (106), Heart (99), Ear, Nose and Throat Disorders (90), Oral Health(85), Gynaecological Cancer(83), Acute Respiratory Infections(77), Epilepsy(68), Hypertension(68). There were 3468 CSRs cited by the Chinese medical Journals, which of 2998 CSRs were cited once. A total of 450 CSRs were cited more than twice. The Chinese articles citing CSRs increased dramatically from 2 articles in the year of 2000 to 560 articles in 2011. In the 600 Chinese medical journals included by CSCD only 158 journals cited CSRs counting for 26%. The top five Chinese medical journals cited CSRs were: Chinese Journal of Evidence-Based Medicine (656), Chinese Journal of Tissue Engineering Research (240), World Journal of Gastroenterology (176), The Journal of Evidence-Based Medicine (173), Chinese Journal of Practical Gynecology and Obstetrics (123). Conclusions: The application of Cochrane reviews in China is still limited and need to be improved.